carnitine has been researched along with Gelineau Syndrome in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "L-carnitine treatment significantly improved the total time for dozing off during the daytime, calculated from the sleep logs, compared with that of placebo-treated periods." | 6.78 | Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial. ( Honda, M; Ikesaki, A; Inoue, Y; Kawamura, H; Miyagawa, T; Obuchi, M; Ozaki, A; Tokunaga, K, 2013) |
| "Blood samples from 57 NT1, 51 other hypersomnia patients, and 61 healthy controls were analyzed." | 5.72 | Low carnitine palmitoyltransferase 1 activity is a risk factor for narcolepsy type 1 and other hypersomnia. ( Honda, M; Honda, Y; Miyagawa, T; Shigematsu, Y; Shimada, M; Tokunaga, K, 2022) |
| "Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness, cataplexy, and REM sleep abnormalities." | 5.37 | Abnormally low serum acylcarnitine levels in narcolepsy patients. ( Honda, M; Honda, Y; Kawashima, M; Miyadera, H; Miyagawa, T; Shimada, M; Tanaka, S; Tokunaga, K, 2011) |
| "L-carnitine treatment significantly improved the total time for dozing off during the daytime, calculated from the sleep logs, compared with that of placebo-treated periods." | 2.78 | Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial. ( Honda, M; Ikesaki, A; Inoue, Y; Kawamura, H; Miyagawa, T; Obuchi, M; Ozaki, A; Tokunaga, K, 2013) |
| "Blood samples from 57 NT1, 51 other hypersomnia patients, and 61 healthy controls were analyzed." | 1.72 | Low carnitine palmitoyltransferase 1 activity is a risk factor for narcolepsy type 1 and other hypersomnia. ( Honda, M; Honda, Y; Miyagawa, T; Shigematsu, Y; Shimada, M; Tokunaga, K, 2022) |
| "Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness, cataplexy, and REM sleep abnormalities." | 1.37 | Abnormally low serum acylcarnitine levels in narcolepsy patients. ( Honda, M; Honda, Y; Kawashima, M; Miyadera, H; Miyagawa, T; Shimada, M; Tanaka, S; Tokunaga, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Honda, M | 3 |
| Shigematsu, Y | 1 |
| Shimada, M | 2 |
| Honda, Y | 2 |
| Tokunaga, K | 3 |
| Miyagawa, T | 3 |
| Romigi, A | 1 |
| Liguori, C | 1 |
| Izzi, F | 1 |
| Albanese, M | 1 |
| Marchi, A | 1 |
| Mancini, C | 1 |
| Tarquini, E | 1 |
| Mercuri, NB | 1 |
| Placidi, F | 1 |
| Miyadera, H | 1 |
| Tanaka, S | 1 |
| Kawashima, M | 1 |
| Berner, J | 1 |
| Kawamura, H | 1 |
| Obuchi, M | 1 |
| Ikesaki, A | 1 |
| Ozaki, A | 1 |
| Inoue, Y | 1 |
1 trial available for carnitine and Gelineau Syndrome
| Article | Year |
|---|---|
Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial.
Topics: Administration, Oral; Adult; Carnitine; Cross-Over Studies; Double-Blind Method; Fatty Acids; Female | 2013 |
4 other studies available for carnitine and Gelineau Syndrome
| Article | Year |
|---|---|
Low carnitine palmitoyltransferase 1 activity is a risk factor for narcolepsy type 1 and other hypersomnia.
Topics: Carnitine; Carnitine Acyltransferases; Carnitine O-Palmitoyltransferase; Disorders of Excessive Somn | 2022 |
Oral L-carnitine as treatment for narcolepsy without cataplexy during pregnancy: a case report.
Topics: Adult; Carnitine; Female; Humans; Narcolepsy; Pregnancy; Pregnancy Complications | 2015 |
Abnormally low serum acylcarnitine levels in narcolepsy patients.
Topics: Adult; Carnitine; Carnitine O-Palmitoyltransferase; Case-Control Studies; Female; Gene Expression; G | 2011 |
Sodium oxybate intolerance associated with familial serum acylcarnitine elevation.
Topics: Acyl-CoA Dehydrogenase; Carnitine; Child; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged | 2013 |